{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:35:19Z","timestamp":1780108519349,"version":"3.54.0"},"reference-count":38,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T00:00:00Z","timestamp":1258416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T00:00:00Z","timestamp":1258416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Nephrol"],"published-print":{"date-parts":[[2010]]},"abstract":"<jats:p>&lt;i&gt;Background\/Aims:&lt;\/i&gt; Inhibiting nonenzymatic glycation with GLY-230 lowers glycated albumin without affecting hyperglycemia and ameliorates renal dysfunction in the &lt;i&gt;db\/db&lt;\/i&gt; mouse, but the effects of this compound in man have not been assessed. We report results from the first clinical trial in patients with diabetes of this new glycation inhibitor. &lt;i&gt;Methods:&lt;\/i&gt; 21 diabetic men were randomly assigned to receive a total dose of 250, 500 or 750 mg of GLY-230 or placebo (1:1:1:1.2 ratio) daily for 14 days to evaluate safety and the effect of drug on plasma concentrations of glycated albumin and on urinary albumin. &lt;i&gt;Results:&lt;\/i&gt; GLY-230 dose-responsively decreased glycated albumin in all participants, in whom HbA1c did not change. Among participants exhibiting microalbuminuria at baseline, mean albumin excretion significantly decreased in patients receiving GLY-230 (\u00b5g albumin\/mg creatinine = 61.4 \u00b1 15.8 and 29.8 \u00b1 10.4 at baseline and completion, respectively; p = 0.001), but not placebo. There were no serious adverse events or laboratory abnormalities, and all safety parameters remained within normal limits. &lt;i&gt;Conclusions:&lt;\/i&gt; This first-in-diabetic man study indicates that GLY-230 lowers glycated albumin and that this decrease is associated with a reduction in urine albumin excretion in patients with preexisting microalbuminuria. These data encourage further evaluation of GLY-230 in diabetic renal dysfunction.<\/jats:p>","DOI":"10.1159\/000259897","type":"journal-article","created":{"date-parts":[[2009,11,18]],"date-time":"2009-11-18T10:50:47Z","timestamp":1258541447000},"page":"110-116","source":"Crossref","is-referenced-by-count":16,"title":["Anti-Glycation and Anti-Albuminuric Effects of GLY-230 in Human Diabetes"],"prefix":"10.1159","volume":"31","author":[{"given":"Laurence","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pilar Solano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Meneghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margo P.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2009,11,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337%2Fdiacare.21.9.1414"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS0272-6386%2899%2970035-1"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038%2Fki.1993.95"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1172%2FJCI111523"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337%2Fdiabetes.39.9.1057"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038%2Fki.1986.82"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337%2Fdiabetes.43.11.1358"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2362.1994.tb01056.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199309303291401"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM200109203451209"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199311113292004"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa011303"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa011489"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa042274"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1523-1755.2002.00352.x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1523-1755.2001.059002673.x"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1006%2Fbbrc.2001.4821"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2337%2Fdiabetes.52.4.1023"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1523-1755.1998.00815.x"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2362.2002.01011.x"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2337%2Fdiabetes.48.12.2446"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1523-1755.2005.00567.x"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1152%2Fajprenal.00201.2006"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016%2F0076-6879%2884%2906010-9"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038%2Fki.2008.68"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1172%2FJCI119163"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1523-1755.2004.00636.x"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00125-002-0946-y"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2337%2Fdiabetes.52.12.2969"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1523-1755.2001.0590062104.x"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfg545"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2337%2Fdiacare.25.2.406"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2337%2Fdiabetes.43.5.649"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa021835"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2337%2Fdiacare.20.10.1576"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2896%2910244-0"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016%2FS0002-9343%2899%2980226-5"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa0708379"}],"container-title":["American Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/259897","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/259897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T21:25:21Z","timestamp":1745443521000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000259897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,17]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2010,2,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000259897","archive":["Portico"],"relation":{},"ISSN":["0250-8095","1421-9670"],"issn-type":[{"value":"0250-8095","type":"print"},{"value":"1421-9670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,17]]}}}